Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PMDA Sets Target Duration of SaMD Priority Reviews to 6 Months in FY2024 Plan
The Pharmaceuticals and Medical Devices Agency (PMDA) has set a target of six months for the total review period of products filed under the software as a medical device (SaMD) priority review system. This plan was presented at a steering…
To read the full story
Related Article
- Panel OKs 3 Products for 1st SaMD Priority Review Designations
March 29, 2023
- Japan to Roll Out Pilot Program for SaMD Priority Review System
September 7, 2022
REGULATORY
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
- Japan Backs Calquence-Venclexta Regimen for Untreated CLL via Label Updates
July 22, 2026
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…